pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute for clinical programs — 187 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
George Institute for projects
187 ClinicalTrials.gov programs sponsored by George Institute for.
George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PRESTO
The George Institute
T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery
1 trial -
PROICM 2019-03 MES
The George Institute
Malignant Peritoneal Mesothelioma
1 trial -
PROICM 2020-04 GAB
The George Institute
local advenced pancreatic adenocarcinoma
1 trial -
PROICM 2021-02 GAB
The George Institute
Metastatic pancreatic adenocarcinoma
1 trial -
PROICM 2021-04 REL
The George Institute
Neuroendocrine tumor
1 trial -
Pemazyre 4.5 mg tablets
The George Institute
locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
1 trial -
Pentasa Sachet depotgranulat for Lynch syndrome, which is increa…
The George Institute
Lynch syndrome, which is increasing the risk of developing colorectal cancer
1 trial -
Plasma rich in growth factors
The George Institute
Low Reserve Ovarian
1 trial -
Protocol number 8
The George Institute
Glioblstoma WHO grade IV
1 trial -
QUINTIS
The George Institute
Metastatic Colorectal Cancer without liver metastases
1 trial -
RIAlta
The George Institute
TUBERCULOSIS
1 trial -
RML-TB
The George Institute
Bacilliferous pulmonary tuberculosis
1 trial -
S095031-210
The George Institute
Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation
1 trial -
S095032-211
The George Institute
IDH1-mutant Glioma, IDH2-mutant Glioma
1 trial -
S227928
The George Institute
"Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"
1 trial -
S230815 Solution for injection 10mg/ml
The George Institute
KCNT1-related Developmental and Epileptic Encephalopathy
1 trial -
SOLARIS
The George Institute
advanced stage hepatocellular carcinoma
1 trial -
SPLFIO-174
The George Institute
Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC
1 trial -
Suspension of autologous mononuclear cells separated from bone marrow aspirate
The George Institute
chronic limb-threatening ischemia, diabetic foot ulcers
1 trial -
Sustanon 250, solution injectable
The George Institute
Androgen deficiency, palliative care
1 trial -
TEMOZOLOMIDE
The George Institute
Diffuse low-grade gliomas
1 trial -
THYMOGLOBULINE for haematological malignancies
The George Institute
haematological malignancies
1 trial -
TRAP-BTC
The George Institute
cholangiocarcinoma or gallbladder carcinoma
1 trial -
TREMELIMUMAB, DURVALUMAB
The George Institute
MSS and MSI colorectal and endometrial tumors
1 trial -
Tarlatamab, Tarlatamab
The George Institute
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
Locally advanced cervical cancer
1 trial -
TolDec
The George Institute
Multiple sclerosis
1 trial -
U1111-1305-0044
The George Institute
Early triple-negative breast cancer (TNBC)
1 trial -
UC-BCG-2213
The George Institute
Triple negative breast cancer
1 trial -
UKD-IKF-Double-T
The George Institute
relapsed/refractory Large B-Cell Lymphoma
1 trial -
UKT-IKF-DEPECA-1
The George Institute
locally advanced or metastatic penile squamous cell carcinoma
1 trial -
URSODEOXYCHOLIC ACID
The George Institute
Hepatorenal polycystic diseases
1 trial -
VESANOID 10 mg, capsule molle
The George Institute
Oligometastatic solid cancer
1 trial -
VHIO17002
The George Institute
Subjects with advanced solid tumour
1 trial -
VHIO19001
The George Institute
Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)
1 trial -
VHIO23001
The George Institute
Metastatic colorectal cancer
1 trial -
VHIO23002
The George Institute
Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.
1 trial -
VHIO24002
The George Institute
Patients with localized renal cell carcinoma
1 trial -
Valemetostat Tosylate, Valemetostat Tosylate
The George Institute
Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.
1 trial -
[18F]PI-2620
The George Institute
Progressive supranuclear palsy, Parkinson's disease
1 trial -
[18F]PI-2620
The George Institute
Down Syndrome., Alzheimer´s Disease.
1 trial -
[18F]PI-2620
The George Institute
Down Syndrome, Alzheimer disease
1 trial -
lurbinectedin for Advanced/Recurrent Endometrial…
The George Institute
Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy
1 trial
Frequently asked questions
How many clinical projects does George Institute for have?
187 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.